Naris Nilubol, M.D., F.A.C.S.
Team Member of:
Dr. Nilubol is a surgeon-scientist specialized in endocrine oncology surgery and clinical research involving thyroid, parathyroid, adrenal, and neuroendocrine tumors. His laboratory research focus includes the identification of novel targeted therapeutics in endocrine cancers and novel cancer drug delivery methods by targeting tumor microenvironment.
1) endocrine surgery, 2) novel therapeutics in endocrine cancers, 3) cancer drug delivery,
4) neuroendocrine tumors, 5) thyroid cancer, 6) adrenal tumors
Dr. Nilubol is the Principle Investigator of the protocol that comprehensively analyze molecular alterations in endocrine cancers that lead to tumor progression and metastasis. He will be the Principle Investigator that studies the von Hippel-Lindau disease (VHL)-associated pancreatic neuroendocrine tumors that aim to understand the molecular mechanisms involved in early metastasis by studying metabolomics and exosomes
Dr. Nilubol’s research program focuses on the identification of novel targeted therapeutics in endocrine cancers such as adrenocortical cancer and aggressive variants of thyroid cancers. Patients with these rare and aggressive cancers do not have treatment options with durable response. Dr. Nilubol collaborates with a number of NIH intramural investigators and uses the quantitative high-throughput drug screening method to identify candidate compounds from several pharmaceutical libraries containing approved drugs and natural compounds. Candidate compounds are being investigated in preclinical studies with the goal to translate the effective combinations of drugs to clinical trials in patients with advanced endocrine cancers. However, most of newly-discovered drugs do not show anti-tumor efficacy because there are many characteristics solid cancers that prohibit an effective drug delivery. Thus, Dr. Nilubol’s research focuses on targeting tumor microenvironment to reduce interstitial fluid pressure and increase drug delivery. To accomplish this goal, he utilizes gold nanomedicine carrying vascular disrupting agent (tumor necrosis factor alpha) specifically targeting tumor cells and its blood supply in collaborating with extramural investigators. The current research aim is to understand how TNF-α works on tumor microenvironment and how to induce the such response in tumors refractory to TNF-α. The nanomedicine carrying TNF-α is being evaluated for a clinical grade production for a phase II clinical trial in patients with advanced endocrine cancers.
Selected Recent Publications
Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.J Natl Cancer Inst. 110(9): 1019-1029, 2018. [ Journal Article ]
Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.Oncotarget. 9(68): 33030-33042, 2018. [ Journal Article ]
- Oncotarget. 9(87): 35723-35725, 2018. [ Journal Article ]
High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy.Surgery. 165(1): 124-128, 2019. [ Journal Article ]
- Thyroid. 29(1): 79-92, 2018. [ Journal Article ]
Dr. Nilubol graduated from Chulalongkorn University Medical Center, Bangkok, Thailand with honors. He completed a surgery research fellowship followed by a general surgery training in 2005 at The Mount Sinai Hospital, New York, NY. Following surgery residency, Dr. Nilubol completed the Endocrine Oncology Surgery fellowship at Rush University Medical Center, Chicago, IL. Dr. Nilubol was on faculty at Mount Sinai Hospital, NY, before being recruited to NCI. In 2011, Dr. Nilubol received the Paul LoGerfo Research Award from the American Association of Endocrine Surgeons for the project involving the identification of novel treatments in adrenocortical cancer. There are over 100 peer-reviewed publications and several book chapters that Dr. Nilubol has authored.
|Dipranjan Laha Ph.D.||Postdoctoral Fellow (Visiting)|
|Sheelu Varghese Ph.D.||Special Volunteer|